Tirzepatide Maintenance Dose After Weight Loss: What the Trials Show
Tirzepatide maintenance dose, short answer: the dose that took the weight off, or 5 mg. In SURMOUNT-MAINTAIN (Lilly, The Lancet, 2026), people who stayed on 10 or 15 mg kept all of their loss for another year; those who dropped to 5 mg kept all but 5.6 kg on average. Stopping, in SURMOUNT-4, brought back 14.0 percent of body weight.
Best vendor for tirzepatide right now: Amino Club, Code 100: 20% off.
Bureau Score 4.7, 0 of 1 independent tests passed (Finnrick). Compare every store. Reader codes were checked on the vendor's cart; offer terms are the vendor's and can change. Affiliate link: we earn a commission if you order. Laboratory research use only, not for human use.
Most of what is written about tirzepatide covers getting to a dose. Far less covers what happens once the weight has come off, which is where the more consequential decision sits. There is a trial that speaks directly to it, and its answer is uncomfortable: stopping is not a neutral act.
This page covers what SURMOUNT-4 and SURMOUNT-MAINTAIN measured, what a maintenance dose is and is not, whether 5 mg is enough, every-other-week dosing, and the practical shape of a step down for anyone determined to come off. For the escalation side see the tirzepatide dosage guide, and for the results curve tirzepatide before and after. This is research use information and none of it is medical advice.
The Trial That Answers This
SURMOUNT-4 was built for exactly this question. All 670 participants took tirzepatide for a 36 week lead-in, reaching a mean weight reduction of 20.9 percent. They were then randomised: half continued, half switched to placebo, for a further 52 weeks.
| Arm | Weight change, week 36 to week 88 | What it means |
|---|---|---|
| Continued tirzepatide | -5.5% | Still losing a year after reaching 20.9% |
| Switched to placebo | +14.0% | Most of the loss reversed within a year |
A 19.4 percentage point gap over 52 weeks is not a subtle finding. The mechanism is the plain reading of it: tirzepatide substitutes for an appetite signal rather than resetting one, so when it clears, appetite returns to roughly where it started while the lower resting energy expenditure of a smaller body does not automatically reverse.
Worth noticing that the continuing arm was still losing weight at week 88, which is the second finding in that table and gets less attention than the regain. The curve in SURMOUNT-1 had not fully levelled by week 72 either.
What a Maintenance Dose Actually Is
The term gets used loosely and it is worth being precise, because it means something different here than it does for many drugs.
There is no separate maintenance formulation and no single designated maintenance dose for tirzepatide. The approved maintenance doses are 5mg, 10mg and 15mg: in other words, the same doses used to produce the loss. A maintenance phase is a decision about goals, not a change in the drug.
In practice people mean one of two things. Either continuing at the dose that produced the result, which is what SURMOUNT-4 tested and the only version with trial evidence behind it. Or reducing to a lower dose that holds weight steady without driving further loss, which was common clinical practice before any trial tested it, and which SURMOUNT-MAINTAIN has now tested at 5 mg (below).
Tirzepatide dose chart: from starting dose to maintenance
The Zepbound label starts at 2.5 mg once a week for four weeks, then steps up by 2.5 mg after at least four weeks on each dose. The recommended maintenance doses are 5, 10 or 15 mg, and 15 mg is the maximum.
| Weeks (at the earliest) | Weekly dose | Role |
|---|---|---|
| 1 to 4 | 2.5 mg | Starting step for tolerability, not a treatment dose |
| 5 to 8 | 5 mg | Lowest maintenance dose; the step-down dose in SURMOUNT-MAINTAIN |
| 9 to 12 | 7.5 mg | Escalation step |
| 13 to 16 | 10 mg | Maintenance dose |
| 17 to 20 | 12.5 mg | Escalation step |
| 21 onward | 15 mg | Maximum and maintenance dose |
Best vendor for tirzepatide right now: Amino Club
30mg vial, $59.99 per vial ($2.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendorsIs 5 mg Enough for Maintenance? SURMOUNT-MAINTAIN
The obvious appeal of stepping down is cost and tolerability. A 5mg maintenance dose is a third of the drug of a 15mg one, and the gastrointestinal burden generally tracks dose.
Until May 2026 there was no trial answer. SURMOUNT-MAINTAIN (NCT06047548) gave 441 adults open-label tirzepatide at their maximum tolerated dose, 10 or 15 mg, for 60 weeks. Those who had lost at least 5 percent and tolerated it were randomised 3:3:2 to stay on that dose, drop to 5 mg, or switch to placebo for another 52 weeks.
| Arm, weeks 60 to 112 | Average weight at week 60 | Average weight at week 112 | Change from the start of the trial |
|---|---|---|---|
| Stayed on 10 or 15 mg | 89.5 kg | 88.7 kg | -25.2 kg (-22.4%) |
| Stepped down to 5 mg | 89.0 kg | 94.6 kg | -19.2 kg (-17.0%) |
Both doses beat placebo on the primary endpoint. The plain reading: 5 mg holds most of the loss, not all of it. On average it gave back 5.6 kg over the year, where the full dose gave back nothing. It also came with fewer stomach side effects in the maintenance year: vomiting in 0.7 percent on 5 mg against 6.5 percent on the full dose, diarrhoea 4.9 against 7.2 percent, nausea 4.2 against 5.8 percent. Figures are from Lilly's results release of 12 May 2026; the full paper is in The Lancet.
That fits SURMOUNT-1, where 5mg on its own produced a 15.0 percent mean reduction, so it is a dose with real effect rather than a token one. 2.5mg is a different case: it is a starting and tolerability step, not a treatment dose, and no trial has tested it for maintenance.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesHow a Step Down Is Usually Structured
For anyone reducing rather than stopping, the shape that most reflects clinical practice (SURMOUNT-MAINTAIN dropped straight from the top dose to 5 mg; the gradual version below is practice, not a tested protocol):
- Hold the result first. Reducing dose while still actively losing confuses two variables at once. Most approaches wait until weight has been stable for a month or two.
- One step at a time. 15mg to 10mg, hold for at least four to eight weeks, then reassess before considering 10mg to 5mg. The four week figure comes from how long steady state takes at any given dose.
- Measure waist as well as weight. Weight fluctuates with fluid; waist tracks the thing that actually matters and moves more slowly.
- Treat a slow regain as information. A kilogram or two of drift is noise. A consistent upward trend over six to eight weeks is the signal that the lower dose is not holding.
- Go back up if it does not hold. Returning to the previous step is an ordinary adjustment, not a failure.
Every Other Week or Once a Month for Maintenance?
The label doses tirzepatide once a week, and no published trial has tested every-other-week or monthly dosing for maintenance. Stretching the interval is a practice reported on forums and by some clinics, not a studied regimen.
The half-life shows why it is a different thing from a lower weekly dose. At about five days, roughly 38 percent of a dose is still there after seven days but only about 14 percent after fourteen (the Bureau's arithmetic from the label half-life). A two-week gap lets the level fall much further between doses, while 5 mg weekly keeps it steadier. If cost is the reason, 5 mg once a week is the lower-cost version with trial data behind it.
Units on your syringe for Tirzepatide
Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup, and the result comes with a link you can share or save.
Open the Tirzepatide calculator peptulator.com, the Bureau's independent toolIf You Are Stopping Entirely
SURMOUNT-4 is the honest starting point: expect appetite to return. It does not happen the day after the last injection, because the half-life is around five days and the drug is substantially cleared only by around 25 days, so it returns gradually over the following month. That gradual onset is what makes it easy to miss until several kilograms have gone back on.
What plausibly reduces the regain, none of it tested as a stopping protocol:
- Protein and resistance training established beforehand. Lean mass is what holds resting energy expenditure up, and it is the single largest modifiable variable after the drug itself.
- Eating structure that does not depend on appetite suppression. Portion habits practised while appetite was suppressed are the things that remain when it is not. See what to eat on a GLP-1.
- A taper rather than a stop. Untested, but it converts an abrupt return of appetite into a gradual one, which is easier to respond to.
- Deciding in advance what triggers a restart. A specific number is more useful than an intention.
The Cost Arithmetic
The honest reason most people ask about maintenance dosing is cost, and it is worth stating rather than talking around. Indefinite treatment at a full dose is expensive at every route, and that is the real constraint for most people rather than tolerability.
A step down to 5mg cuts the drug cost proportionally, which is the main argument in its favour. Route matters more than dose, though: the spread between a cash-price branded carton and a research vial is larger than the spread between 15mg and 5mg. A larger vial bought once is cheaper per milligram than repeated small ones, which matters more on an indefinite protocol than on a 72 week one; PSPeptides carries the 60mg presentation and is the only vendor we track shipping outside the United States. The full comparison is in tirzepatide cost and where to buy tirzepatide, and the dose arithmetic for a reduced dose from an existing vial is in the tirzepatide dosage calculator.
Key Takeaways
- SURMOUNT-4 is the trial that addresses this: after a 36 week lead-in to 20.9 percent loss, continuing produced a further 5.5 percent while stopping produced 14.0 percent regain over 52 weeks.
- There is no separate maintenance formulation. The maintenance doses are the same 5mg, 10mg and 15mg.
- Continuing at the dose that produced the result holds all of it: in SURMOUNT-MAINTAIN the 10 or 15 mg arm kept its full loss for another year.
- Stepping down to 5mg is now tested: it kept all but 5.6 kg of the loss on average over a year, with fewer stomach side effects.
- Every-other-week or monthly dosing has no trial data.
- 2.5mg is a tolerability step, not a maintenance dose.
- After stopping, appetite returns over roughly a month rather than immediately, which is why regain is easy to miss early.
- Lean mass is the largest modifiable variable after the drug itself.
Frequently Asked Questions
What is the maintenance dose of tirzepatide after weight loss?
Either the dose that produced the loss or 5 mg. The approved maintenance doses are 5mg, 10mg and 15mg, the same ones used to produce the loss. In SURMOUNT-MAINTAIN, people who stayed on 10 or 15 mg kept all of their loss for a further year, and those who stepped down to 5 mg kept all but 5.6 kg on average. Stopping, in SURMOUNT-4, brought back 14.0 percent of body weight.
What happens if you stop taking tirzepatide?
Appetite returns, and weight generally follows. In SURMOUNT-4, participants who reached a 20.9 percent reduction over a 36 week lead-in and then switched to placebo regained 14.0 percent of body weight over the next 52 weeks, while those who continued lost a further 5.5 percent. The return is gradual rather than immediate, because the half-life is around five days and the drug is substantially cleared only by roughly 25 days.
Can you take a lower dose of tirzepatide to maintain weight loss?
Yes, and since 2026 there is trial data for it. SURMOUNT-MAINTAIN randomised people who had reached their loss on 10 or 15 mg to stay there, drop to 5 mg or switch to placebo for 52 weeks. Both doses beat placebo; 5 mg kept all but 5.6 kg of the loss on average while the full dose kept all of it. 2.5mg is a different case: it is a starting step rather than a treatment dose.
How do you step down a tirzepatide dose?
The shape that most reflects clinical practice is to wait until weight has been stable for a month or two first, then reduce one step at a time, holding each new dose for at least four to eight weeks before reassessing. Four weeks is the minimum because that is roughly how long steady state takes at any given dose. Track waist as well as weight, treat a consistent upward trend over six to eight weeks as the signal that the lower dose is not holding, and return to the previous step if so.
Do you have to take tirzepatide forever?
Not necessarily, but the trial data makes clear that stopping usually means substantial regain, so it should be a planned decision rather than a default. What plausibly reduces regain is having protein intake, resistance training and an eating structure established before stopping, since those are what hold resting energy expenditure up once appetite returns. None of that has been tested as a stopping protocol.
Why do you keep losing weight on tirzepatide after a year?
Because the curve has not finished. In SURMOUNT-1 the weight curve was still descending at around week 72 of a 72 week trial, and in SURMOUNT-4 the arm that continued past the 36 week lead-in lost a further 5.5 percent over the following year. Continued loss well past the first year is the expected pattern rather than an anomaly.
Can you take tirzepatide every other week for maintenance?
No trial has tested it. The label doses tirzepatide once a week, and with a half-life of about five days only around 14 percent of a dose is left after two weeks, so the level swings much more than on a weekly dose. A weekly 5 mg dose is the lower-cost version with trial data behind it.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes